Manufacturing Day 2024

Between the BIOSECURE Act in the US, China’s tightened espionage laws, and worry about Covid-esque global disruption, biopharma companies all over the world are taking a close look at the maps of their supply chains. Some are making the call to move things closer to home. Join our panelists to explore why and how manufacturing is (or is not) shifting domestically.

High demand for pharma manufacturing, driven by patients’ needs and scientific breakthroughs, is creating an industry imperative to provide additional, reliable supply, despite increasing complexities and disruptions. Hear from top CDMO C-suite experts about how they are partnering with innovators to overcome the challenges facing global supply needs, regulatory disruptions, multiple modalities in the development pipeline, complexity, and rising costs. Featuring guest speakers: John Chiminski, former Catalent CEO and Chair; Bill Humphries, CEO of Alcami; Christian Jones, CCO of Nanoform; and Hayley Crowe, EVP, Pharma at Ecolab; and moderated by Kurt Nielsen, Ph.D., former CEO at Pii and CTO at Catalent.

The rush for GLP1 drugs and subsequent shortages have opened the door for compounding pharmacies to make versions of the medication. But the quality of those versions is sometimes questionable — as is the legality. FDA has issued warnings, state boards of pharmacy have put out notices, and drugmakers have filed lawsuits. What comes next? Join us as reporter Nicole DeFeudis talks with the head of the National Association of Boards of Pharmacy about the messy landscape.